Capital Investment Advisors LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Capital Investment Advisors LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 8.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 593,359 shares of the biopharmaceutical company’s stock after selling 55,559 shares during the period. Capital Investment Advisors LLC’s holdings in Pfizer were worth $15,742,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. GHP Investment Advisors Inc. raised its position in shares of Pfizer by 5.2% during the 2nd quarter. GHP Investment Advisors Inc. now owns 12,589 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 620 shares during the period. Parallel Advisors LLC lifted its stake in shares of Pfizer by 19.1% in the 2nd quarter. Parallel Advisors LLC now owns 108,180 shares of the biopharmaceutical company’s stock valued at $3,027,000 after purchasing an additional 17,370 shares during the last quarter. Thoroughbred Financial Services LLC increased its position in shares of Pfizer by 102.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 32,173 shares of the biopharmaceutical company’s stock worth $900,000 after purchasing an additional 16,313 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of Pfizer by 9.0% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 328,170 shares of the biopharmaceutical company’s stock worth $9,182,000 after purchasing an additional 27,178 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in shares of Pfizer by 2.4% during the second quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock worth $287,077,000 after buying an additional 238,850 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Price Performance

NYSE:PFE traded down $0.23 during trading hours on Monday, reaching $26.49. 10,957,562 shares of the company traded hands, compared to its average volume of 31,735,346. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $150.12 billion, a P/E ratio of 35.80, a P/E/G ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm’s 50-day moving average is $26.18 and its 200-day moving average is $28.04.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 232.43%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.